NCT00828022

Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer

A Single-Institution, Open-Label, Single-Arm phase1/2 Study of Measles Vaccine as Consolidation in Patients With Measles Virus-Positive, Stage 3B/4 Non-Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Soroka University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with pleural effusion) or metastatic (stage 4) tumors in remission.

Detailed description

This is a single-institution, non-randomized phase 1/2 study in patients with locally-advanced or metastatic NSCLC in remission after receiving standard systemic chemotherapy of four cycles of combination chemotherapy consisting of four cycles of cisplatin combined with vinorelbine.

Conditions

• Non-Small Cell Lung Cancer
• Measles

Interventions

Type	Name	Description
BIOLOGICAL	attenuated measles vaccine	4-week apart, two vaccines starting 4 weeks after last chemotherapy

Timeline

• Start date: 2009-03-01
• First posted: 2009-01-23
• Last updated: 2009-01-23

Locations

1 site across 1 country: Israel